Lindbrook Capital’s Relay Therapeutics RLAY Stock Holding History

Lindbrook Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$5.75K	Buy	+2,195	New	+$8.6K	﹤0.01%	1900
2024 Q3	–	Sell	-645	Closed	-$4.21K	–	2896
2024 Q2	$4.21K	Buy	645 +304	+89%	+$2.08K	﹤0.01%	2081
2024 Q1	$2.83K	Sell	341 -106	-24%	-$1.03K	﹤0.01%	2121
2023 Q4	$4.92K	Buy	447 +232	+108%	+$1.96K	﹤0.01%	1898
2023 Q3	$1.81K	Buy	215 +65	+43%	+$699	﹤0.01%	2164
2023 Q2	$1.88K	Buy	150 +22	+17%	+$274	﹤0.01%	2169
2023 Q1	$2.11K	Buy	128 +116	+967%	+$2.08K	﹤0.01%	2225
2022 Q4	$179	Sell	12 -253	-95%	-$4.84K	﹤0.01%	2741
2022 Q3	$6K	Buy	265 +147	+125%	+$3.23K	﹤0.01%	1588
2022 Q2	$2K	Buy	118 +16	+16%	+$343	﹤0.01%	2040
2022 Q1	$3K	Buy	+102	New	+$2.48K	﹤0.01%	1868

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Lindbrook Capital's RLAY Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Relay Therapeutics (RLAY) in Q1 2025: 2,195 shares worth $5.75K. The stake represents ﹤0.01% of the portfolio and ranks #1900 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in RLAY as recently as Q2 2024.

Lindbrook Capital first reported a position in RLAY in Q1 2022 and has held it in 11 quarters since. The position peaked at $6K in Q3 2022. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

Lindbrook Capital held 2,195 shares of Relay Therapeutics worth $5.75K as of Q1 2025.
Relay Therapeutics was a new Lindbrook Capital position in Q1 2025.
Relay Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1900 holding.
Lindbrook Capital first reported a position in Relay Therapeutics in Q1 2022 and has held it in 11 quarters since.
Lindbrook Capital's Relay Therapeutics position peaked at $6K in Q3 2022.
207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.